Financhill
Buy
54

ACIU Quote, Financials, Valuation and Earnings

Last price:
$2.02
Seasonality move :
-4.27%
Day range:
$2.01 - $2.11
52-week range:
$1.43 - $4.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.17x
P/B ratio:
1.88x
Volume:
129.7K
Avg. volume:
118.5K
1-year change:
-49.37%
Market cap:
$202.2M
Revenue:
$31M
EPS (TTM):
-$0.59

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ACIU
AC Immune SA
$369.1K -$0.24 215.05% -22.94% $9.18
ADCT
ADC Therapeutics SA
$17.7M -- 2.37% -- $8.20
ADXN
Addex Therapeutics
$242.8K -- 2.35% -- $30.00
CRSP
CRISPR Therapeutics AG
$6M -$1.28 -96.36% -7.71% $81.75
NLSP
NLS Pharmaceutics
-- -- -- -- --
ONC
BeOne Medicines
$1.1B -$0.74 33.1% -70.04% $330.97
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ACIU
AC Immune SA
$2.01 $9.18 $202.2M -- $0.00 0% 6.17x
ADCT
ADC Therapeutics SA
$2.71 $8.20 $268.8M -- $0.00 0% 3.69x
ADXN
Addex Therapeutics
$9.00 $30.00 $9.6M 1.75x $0.00 0% 24.63x
CRSP
CRISPR Therapeutics AG
$47.49 $81.75 $4.1B -- $0.00 0% --
NLSP
NLS Pharmaceutics
$2.79 -- $12.6M -- $0.00 0% --
ONC
BeOne Medicines
$241.20 $330.97 $26.1B -- $0.00 0% 6.19x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ACIU
AC Immune SA
-- 2.864 -- 1.50x
ADCT
ADC Therapeutics SA
-91.5% 5.183 81.39% 3.92x
ADXN
Addex Therapeutics
-- 0.971 -- 4.36x
CRSP
CRISPR Therapeutics AG
-- 1.532 -- 21.97x
NLSP
NLS Pharmaceutics
-- 5.297 -- --
ONC
BeOne Medicines
20.88% 0.693 3.14% 1.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ACIU
AC Immune SA
-- -$21.5M -42.34% -42.34% -1916.67% -$21.3M
ADCT
ADC Therapeutics SA
$21M -$28.2M -4172.63% -- -113.78% -$56.6M
ADXN
Addex Therapeutics
-- -$674K 91.08% 91.08% -2836.3% -$665.6K
CRSP
CRISPR Therapeutics AG
-$57.5M -$148.4M -18.65% -18.65% -184.54% -$54.2M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --
ONC
BeOne Medicines
$952.3M $11.1M -8.9% -11.54% 0.99% -$72.3M

AC Immune SA vs. Competitors

  • Which has Higher Returns ACIU or ADCT?

    ADC Therapeutics SA has a net margin of -1922.12% compared to AC Immune SA's net margin of -167.59%. AC Immune SA's return on equity of -42.34% beat ADC Therapeutics SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
    ADCT
    ADC Therapeutics SA
    91.05% -$0.36 -$124.4M
  • What do Analysts Say About ACIU or ADCT?

    AC Immune SA has a consensus price target of $9.18, signalling upside risk potential of 356.6%. On the other hand ADC Therapeutics SA has an analysts' consensus of $8.20 which suggests that it could grow by 202.58%. Given that AC Immune SA has higher upside potential than ADC Therapeutics SA, analysts believe AC Immune SA is more attractive than ADC Therapeutics SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    ADCT
    ADC Therapeutics SA
    4 0 0
  • Is ACIU or ADCT More Risky?

    AC Immune SA has a beta of 1.574, which suggesting that the stock is 57.401% more volatile than S&P 500. In comparison ADC Therapeutics SA has a beta of 1.963, suggesting its more volatile than the S&P 500 by 96.33%.

  • Which is a Better Dividend Stock ACIU or ADCT?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADC Therapeutics SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. ADC Therapeutics SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or ADCT?

    AC Immune SA quarterly revenues are $1.1M, which are smaller than ADC Therapeutics SA quarterly revenues of $23M. AC Immune SA's net income of -$21.2M is higher than ADC Therapeutics SA's net income of -$38.6M. Notably, AC Immune SA's price-to-earnings ratio is -- while ADC Therapeutics SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 6.17x versus 3.69x for ADC Therapeutics SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    6.17x -- $1.1M -$21.2M
    ADCT
    ADC Therapeutics SA
    3.69x -- $23M -$38.6M
  • Which has Higher Returns ACIU or ADXN?

    Addex Therapeutics has a net margin of -1922.12% compared to AC Immune SA's net margin of -2841.85%. AC Immune SA's return on equity of -42.34% beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
    ADXN
    Addex Therapeutics
    -- -$1.33 $13.1M
  • What do Analysts Say About ACIU or ADXN?

    AC Immune SA has a consensus price target of $9.18, signalling upside risk potential of 356.6%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 233.27%. Given that AC Immune SA has higher upside potential than Addex Therapeutics, analysts believe AC Immune SA is more attractive than Addex Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    ADXN
    Addex Therapeutics
    0 0 0
  • Is ACIU or ADXN More Risky?

    AC Immune SA has a beta of 1.574, which suggesting that the stock is 57.401% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.620, suggesting its more volatile than the S&P 500 by 61.965%.

  • Which is a Better Dividend Stock ACIU or ADXN?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or ADXN?

    AC Immune SA quarterly revenues are $1.1M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. AC Immune SA's net income of -$21.2M is lower than Addex Therapeutics's net income of -$1.6M. Notably, AC Immune SA's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is 1.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 6.17x versus 24.63x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    6.17x -- $1.1M -$21.2M
    ADXN
    Addex Therapeutics
    24.63x 1.75x $62.3K -$1.6M
  • Which has Higher Returns ACIU or CRSP?

    CRISPR Therapeutics AG has a net margin of -1922.12% compared to AC Immune SA's net margin of -106.6%. AC Immune SA's return on equity of -42.34% beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
  • What do Analysts Say About ACIU or CRSP?

    AC Immune SA has a consensus price target of $9.18, signalling upside risk potential of 356.6%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 72.15%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    CRSP
    CRISPR Therapeutics AG
    12 10 1
  • Is ACIU or CRSP More Risky?

    AC Immune SA has a beta of 1.574, which suggesting that the stock is 57.401% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.751, suggesting its more volatile than the S&P 500 by 75.105%.

  • Which is a Better Dividend Stock ACIU or CRSP?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or CRSP?

    AC Immune SA quarterly revenues are $1.1M, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. AC Immune SA's net income of -$21.2M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, AC Immune SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 6.17x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    6.17x -- $1.1M -$21.2M
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
  • Which has Higher Returns ACIU or NLSP?

    NLS Pharmaceutics has a net margin of -1922.12% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -42.34% beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About ACIU or NLSP?

    AC Immune SA has a consensus price target of $9.18, signalling upside risk potential of 356.6%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 8502.15%. Given that NLS Pharmaceutics has higher upside potential than AC Immune SA, analysts believe NLS Pharmaceutics is more attractive than AC Immune SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is ACIU or NLSP More Risky?

    AC Immune SA has a beta of 1.574, which suggesting that the stock is 57.401% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ACIU or NLSP?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or NLSP?

    AC Immune SA quarterly revenues are $1.1M, which are larger than NLS Pharmaceutics quarterly revenues of --. AC Immune SA's net income of -$21.2M is higher than NLS Pharmaceutics's net income of --. Notably, AC Immune SA's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 6.17x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    6.17x -- $1.1M -$21.2M
    NLSP
    NLS Pharmaceutics
    -- -- -- --
  • Which has Higher Returns ACIU or ONC?

    BeOne Medicines has a net margin of -1922.12% compared to AC Immune SA's net margin of 0.11%. AC Immune SA's return on equity of -42.34% beat BeOne Medicines's return on equity of -11.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
    ONC
    BeOne Medicines
    85.23% -- $4.4B
  • What do Analysts Say About ACIU or ONC?

    AC Immune SA has a consensus price target of $9.18, signalling upside risk potential of 356.6%. On the other hand BeOne Medicines has an analysts' consensus of $330.97 which suggests that it could grow by 37.22%. Given that AC Immune SA has higher upside potential than BeOne Medicines, analysts believe AC Immune SA is more attractive than BeOne Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACIU
    AC Immune SA
    3 0 0
    ONC
    BeOne Medicines
    15 1 0
  • Is ACIU or ONC More Risky?

    AC Immune SA has a beta of 1.574, which suggesting that the stock is 57.401% more volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.143%.

  • Which is a Better Dividend Stock ACIU or ONC?

    AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACIU or ONC?

    AC Immune SA quarterly revenues are $1.1M, which are smaller than BeOne Medicines quarterly revenues of $1.1B. AC Immune SA's net income of -$21.2M is lower than BeOne Medicines's net income of $1.3M. Notably, AC Immune SA's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 6.17x versus 6.19x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACIU
    AC Immune SA
    6.17x -- $1.1M -$21.2M
    ONC
    BeOne Medicines
    6.19x -- $1.1B $1.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Google Stock Double by 2030?
Will Google Stock Double by 2030?

If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…

Why Did David Tepper Sell NVIDIA Stock?
Why Did David Tepper Sell NVIDIA Stock?

In Q1, billionaire David Tepper of Appaloosa Management sold nearly…

Why Is Planet Labs Stock Up Today?
Why Is Planet Labs Stock Up Today?

Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 54x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
NKE alert for Jun 28

Nike [NKE] is up 15.29% over the past day.

Buy
81
KTOS alert for Jun 28

Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.

Sell
44
GDXU alert for Jun 28

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock